scholarly journals A 40-year-old Woman with Hypercalcemia Crisis Caused by Bone Metastasis in Stage IV Breast Cancer

2021 ◽  
Vol 4 (2) ◽  
pp. 117
Author(s):  
Wiharjo Hadisuwarno ◽  
Merlyna Savitri ◽  
Ami Ashariati ◽  
S. Ugroseno Yudho Bintoro ◽  
M. Noor Diansyah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Bone Metastasis ◽  
Stage Iv ◽  
Terminal Stage ◽  
Holistic Management ◽  
Stage Iv Breast Cancer ◽  
Laboratory Examinations ◽  
Cancer Diseases

Breast cancer is still global burden especially for woman with 2.3 million cases every year dan 15% mortality among cancer diseases. In developing countries, most of the cases are diagnosed at terminal stage when metastasis already found. Bone metastasis is the highest among other metastasis sites such as: lung, liver and brain. Bone metastasis will cause hypercalcemia and bone pain as complications.  Both will gradually decrease patient’s quality of life. Comprehensive and holistic management for these complications will reduce deterioration and hopefully increase patient’s quality of life even they were at terminal stage. We describe a 40-year-old woman who got hypercalcemia crisis. Hypercalcemia usually manifest as a consequence of other diseases. Epidemiologically, majority come from metastasis, but can be other diseases, such as multiple myeloma. Interestingly, during medical investigation through her medical history, and physical examination, and laboratory examinations, we conclude that her hypercalcemia crisis was caused by bone metastasis from breast cancer.

Locoregional Therapy for the Primary Tumor in Stage IV Breast Cancer

2017 ◽  
Author(s):  
Sasa M Espino ◽  
Swati Kulkarni
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Systemic Therapy ◽  
Cancer Metastasis ◽  
Stage Iv ◽  
Breast Cancer Metastasis ◽  
Locoregional Therapy ◽  
Stage Iv Breast Cancer ◽  
Prospective Trials

Locoregional therapy, comprising surgery and radiation, has traditionally been reserved for managing symptoms from the primary tumor in women with stage IV breast cancer. However, in recent years, there has been significant interest in expanding the indications of local therapy in women with metastatic breast cancer beyond palliation to prolonging survival. In this review, we first discuss biological hypotheses of breast cancer metastasis that support the use of locoregional therapy in stage IV breast cancer. Second, we summarize the data from the key retrospective studies of locoregional therapy in stage IV breast cancer. Although many of these studies demonstrated a survival advantage over women who received systemic therapy alone, a number of key questions remained unanswered, including the timing, extent, and type of locoregional therapy that would provide maximal benefit to patients with metastatic disease while preserving quality of life. Lastly, three recently completed prospective trials have reported inconsistent results, with two demonstrating no survival advantage over systemic therapy alone and the third showing an increased overall survival after longer follow-up. Three other prospective trials are ongoing and attempt to address the limitations of the retrospective review and determine which class of patients would benefit most from additional intervention. This review contains 8 figures, 4 tables, and 44 references. Key words: axillary surgery, biology of breast cancer metastasis, breast surgery, clinical trials, locoregional therapy, margin status, quality of life, radiation therapy, stage IV breast cancer

Locoregional Therapy for the Primary Tumor in Stage IV Breast Cancer

2017 ◽  
Author(s):  
Sasa M Espino ◽  
Swati Kulkarni
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Systemic Therapy ◽  
Cancer Metastasis ◽  
Stage Iv ◽  
Breast Cancer Metastasis ◽  
Locoregional Therapy ◽  
Stage Iv Breast Cancer ◽  
Prospective Trials

Locoregional therapy, comprising surgery and radiation, has traditionally been reserved for managing symptoms from the primary tumor in women with stage IV breast cancer. However, in recent years, there has been significant interest in expanding the indications of local therapy in women with metastatic breast cancer beyond palliation to prolonging survival. In this review, we first discuss biological hypotheses of breast cancer metastasis that support the use of locoregional therapy in stage IV breast cancer. Second, we summarize the data from the key retrospective studies of locoregional therapy in stage IV breast cancer. Although many of these studies demonstrated a survival advantage over women who received systemic therapy alone, a number of key questions remained unanswered, including the timing, extent, and type of locoregional therapy that would provide maximal benefit to patients with metastatic disease while preserving quality of life. Lastly, three recently completed prospective trials have reported inconsistent results, with two demonstrating no survival advantage over systemic therapy alone and the third showing an increased overall survival after longer follow-up. Three other prospective trials are ongoing and attempt to address the limitations of the retrospective review and determine which class of patients would benefit most from additional intervention. This review contains 8 figures, 4 tables, and 44 references. Key words: axillary surgery, biology of breast cancer metastasis, breast surgery, clinical trials, locoregional therapy, margin status, quality of life, radiation therapy, stage IV breast cancer

scholarly journals BOMET-QoL-10 questionnaire for breast cancer patients with bone metastasis: the prospective MABOMET GEICAM study

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
A. Barnadas ◽  
◽  
M. Muñoz ◽  
M. Margelí ◽  
J. I. Chacón ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Health Status ◽  
Bone Metastasis ◽  
Assessment Tool ◽  
Metastatic Breast ◽  
Perceived Health ◽  
Perceived Health Status ◽  
Patient Reported

Abstract Background Bone metastasis (BM) is the most common site of disease in metastatic breast cancer (MBC) patients. BM impacts health-related quality of life (HRQoL). We tested prospectively the psychometric properties of the Bone Metastasis Quality of Life (BOMET-QoL-10) measure on MBC patients with BM. Methods Patients completed the BOMET-QoL-10 questionnaire, the Visual Analogue Scale (VAS) for pain, and a self-perceived health status item at baseline and at follow-up visits. We performed psychometric tests and calculated the effect size of specific BM treatment on patients´ HRQoL. Results Almost 70% of the 172 patients reported symptoms, 23.3% experienced irruptive pain, and over half were receiving chemotherapy. BOMET-QoL-10 proved to be a quick assessment tool performing well in readability and completion time (about 10 min) with 0–1.2% of missing/invalid data. Although BOMET-QoL-10 scores remained fairly stable during study visits, differences were observed for patient subgroups (e.g., with or without skeletal-related events or adverse effects). Scores were significantly correlated with physician-reported patient status, patient-reported pain, symptoms, and perceived health status. BOMET-QoL-10 scores also varied prospectively according to changes in pain intensity. Conclusions BOMET-QoL-10 performed well as a brief, easy-to-administer, useful, and sensitive HRQoL measure for potential use for clinical practice with MBC patients. Trial registration NCT03847220. Retrospectively registered on clinicaltrials.gov (February the 20th 2019).

scholarly journals Quality of life of Zambian breast cancer women receiving care at the cancer diseases hospital Lusaka

2020 ◽  
Vol 10 (9) ◽  
pp. 57
Author(s):  
Masadza Wezzie ◽  
Siankulu Elaine ◽  
Kawalika Micheal ◽  
Victoria Mwiinga-Kalusopa ◽  
Patricia Katowa-Mukwato
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Sexual Functioning ◽  
Access To Health Care ◽  
Symptom Experience ◽  
Symptom Scale ◽  
Financial Status ◽  
Access To Health ◽  
Cancer Diseases

Background: Breast cancer is the most frequently diagnosed malignancy among women in the world with an estimation of 1.67 million new diagnoses worldwide in 2012 estimated at 25% of all cancers. In Zambia, breast cancer is the second most common cancer affecting women and accounts for 9% of all histologically proven cancers among patients admitted at the country’s only Cancer Diseases Hospital Most of the patients receive multiple treatment modalities; Surgery, Chemotherapy, Radiation Therapy and Hormonal Therapy, each with its own long-term side effects with a potential to affect  the women’s functionality, self-image and sexuality consequently the general quality of life of these women.Methods: A descriptive cross-sectional study design was used to investigate the Quality of Life (QoL) and factors influencing QoL among women with breast cancer receiving care at Zambia’s only Cancer Diseases Hospital. A total of 130 breast cancer patients on treatment who were willing to participate in the study were selected using simple random sampling. Data was collected using the European Organization for Research and Treatment in Cancer Quality of Life Questionnaire (EORTCQLQ–C30) and its breast cancer supplementary measure (QLQ-BR23). The tool assessed QoL across the physical, role, cognitive, emotional, and social functioning and sexual function domains.Results: Overall, just about half (52.5%) of the 130 respondents had high Quality of Life. QoL which was measured by the EORTCQLQ–C30 under the five domains (Physical, role, emotional, cognitive and sexual functioning) was high in four out of the five which scored above the global mean score of 68. Only the emotional functioning domain scored (65) below the mean. Conversely, the symptom scale scored high on all the eight sub items of fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea which signified high symptom experience among respondents. Similarly using the breast cancer supplementary measure (QLQ-BR23), two out of the four functional subscales (body image and sexual functioning) score high than average while sexual enjoyment and future perspectives score low. On the symptom scale, three out of the four scales scored higher than averages, signifying high symptom experience. Demographic characteristics which had significant association with QoL were age (p < .023), level of education (p < .023) and financial status (p < .000). Other factors that had significant association with QoL were type of treatment being received (p < .023), the severity of condition (p < .000), access to health care services (p < .000) and social support (p < .000).Conclusions: A diagnosis of breast cancer and its subsequent treatment affects several facets of a woman’s life ranging from physical, emotional, social and financial aspects consequently affecting the entire QoL. However the QoL varies and is influenced by a number of factors including age at diagnosis of cancer, level of education, financial status, type of treatment received, severity of the condition, access to health care facilities and social support. Therefore any intervention aimed at improving the QoL should be multidimensional.

Sign in / Sign up

Export Citation Format

Share Document